Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Kunnen we nog verrast worden? De cijfers zouden we toch wel moeten kennen! Het zal dus wat mij betreft hooguit de outlook zijn die kan meespelen. Laat het dus maar eens een positieve zijn!
Vergeet de fusie, overname niet of willen ze zelf groeien? Dit jaar was er ruimte voor 15 tot 18 man had ik een tijdje geleden gelezen. Gr Arie de Beuker
Goede morgen allen, ik wens u een fijne dag met veel positieve vibes. Ik verwacht een eindstand vandaag op 12,80. gr. Eifeler
Hoi allemaal, ik heb een paar keer een order rond de 1025 proberen te krijgen . Helaas niet gelukt. Ben natuurlijk benieuwd naar de cijfers en de outlook van vandaag! Suc6 allemaal en moge het goede cijfers zijn!
Revenue: $33.9m (2017: $28.5m) EBITDA: $8.9m (2017: $8.0m) PBT: $6.4m (2017: $5.1m) Net cash: $16.7m (2017: $9.5m) Financial outperformance underlines continuing momentum in the business. 18 new customer wins (13 in the prior year). Full year 2019 revenue visibility of $20.6m (2017: $19.3m). Mentioned in 22 research reports from leading industry voices such as Gartner and Forrester Research. Vision extended from innovation to helping major enterprises achieve their strategic goals, dramatically expanding horizons and potential. Dividend proposed of 3.25p per share (2017: 2.5p).
Mooie cijfers! Maar de forse groei lijkt er een beetje uit dit is waarom ik uitgetapt ben. Blijft een mooi aandeel . Ben benieuwd en suc6 allemaal
PE is nu 22 met minder snelle groei hogere kosten. Is maar mijn mening aan de maat. Dus ik blijf even aan de zijlijn. Hoop voor jullie dat ik mis zit. Maar dan ben ik tevreden met mijn winst
Voor mij is de Outlook het belangrijkste, hoe is the time to accelerator investment. We have ambitious planes!! Overnames!
Plus 30%, mooi I would like to close this statement by announcing a proposal to increase our dividend from 2.5p to 3.25p per share. I am delighted to be following through on the commitment made last year to maintain a progressive dividend policy, which the board believes underlines our maturity as a business.”
Ga er maar van uit dat de koersbeweging van de afgelopen dagen volledig georkestreerd zijn. Daarnaast … In Januari stond er zelfs even 14,40 op de borden. Was dat zo overdreven? Wellicht, maar het enorme verschil tussen de twee uitersten (dik 4 pond) valt voor mij niet te verklaren aan de hand van de cijfers. Noem het handel, maar het is vooral speculatie en manipulatie.
De markt kan deze grotendeels al bekende cijfers niet echt waarderen. Zo ook de forse dividend verhoging van 30 % niet.
denk in de komende weken de 800 dab stap ik weer in
An excellent performance in FY 2018……provides a platform for future growth Sopheon has reported full year results in line with its January trading update and a little ahead of our estimates which we upgraded at that time. Sopheon saw a strong finish to 2018 with a number of transactions further underlining the adaptability and flexibility of the Accolade platform. Overall, Sopheon won 18 new customers compared to 13 in 2017. Chairman Barry Mence says that Sopheon has ‘a unique opportunity’ to build on its category leader status by accelerating investment. Revenue visibility is already at $20.6 million for FY 2019E and the announcement highlights a sales pipeline which includes a number of ‘large opportunities’. Management continues to look at acquisition opportunities to augment organic growth. After an excellent FY 2018 which has enabled Sopheon to increase its dividend by 30%, we note the Board’s intention to speed up investment during the year and we make changes to our FY 2019E estimates which leave Adj EBITDA a touch lower than our previous estimate. We introduce FY 2020E estimates which reflect a resumption of good growth in Adj EBITDA on the expectation of moderated investment spend ......... ......... FY 2018 results A strong year brings the opportunity for accelerated investment Sopheon’s strong performance in FY 2018 included the addition of 18 new customers (of which 5 were SaaS) compared to 13 in FY 2017. Sopheon’s blue chip customer base features increasingly enterprise-focused customer relationships and over two-thirds of its annual revenues come from existing customers. Sopheon sells Accolade predominantly on perpetual licences with annual maintenance and hosting fees. Few deals are pure SaaS although there is a good level of recurring income. With further increases in maintenance and hosting, Sopheon ended 2018 with a total recurring revenue run rate of $15m (compared to $12m the year before) of which approximately $3m is SaaS and hosting ............. ............. Estimates After a strong FY 2018 we note 1) current revenue visibility and 2) the Board’s intention to speed up investment during the year. In addition, our adjusted numbers are now net of Share Based Payments which look set to remain at the higher level seen in FY 2018 of around $0.5m. They also contain a nominal tax charge although we note Sopheon’s substantial potential deferred tax asset. In combination, we make a minor upgrade to our FY 2019E revenue estimate but increase cost expectations further which leaves Adj EBITDA for FY 2019E a touch below our previous restated estimate and a little lower than the level reported for FY 2018. We introduce FY 2020E estimates which reflect a resumption of good growth in Adj EBITDA. Summary and conclusion The 2018 results reported this morning represent another major step forward in financial performance – the group continues to expand its client base, to sell into ever more end use cases, and to evolve the reach of its offering. Sopheon has, for some time, been seeking to invest further in its teams, and we continue to forecast such investment – hopeful that 2019 will allow the group to hire a good number of new, high quality, members of its team. We expect further progress in terms of customers, projects and revenue, but we have structured our upgrades as shown above, to cater for the potential incremental hires – whose benefit will only likely be felt in later years. We remain believers in the Sopheon strategy, and look forward to further evidence of success during 2019 and beyond.
Iemand toevallig inzage in de Finncap rapportage? bvd
tritace schreef op 21 maart 2019 11:50 :
Iemand toevallig inzage in de Finncap rapportage?
bvd
www.sharesmagazine.co.uk/news/market/...
koersdoel wordt verhoogd van 14 naar 15 pond, maar toch zakken we 13% naar 10 pond. Ik vind de reactie wel wat overdreven eigenlijk. gr. OVI
Waren de cijfers anders dan die van eind Januari? Dan is het dus weer typisch kuddegedrag! Dus stil zitten als je geschoren gaat worden en langzaam uit laten razen, daarna weer langzaam zoals bij Sopheon gebeurt groeien naar een hogere koers. Voor mij geeft het weer kansen om bij te kopen, op naar de half jaar cijfers en het koersdoel van 15 pond!
Gartje, heb al vaker gezegd dit lijkt wel een tussen jaar als 2017. Dit jaar minder winst per aandeel vandaar de daling. Denk echt dat SOOF nog verder kan zaken. Kijk naar de K/W. Suc6
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
880,63
+0,67%
EUR/USD
1,0688
-0,13%
FTSE 100
8.084,04
+0,49%
Germany40^
18.196,30
+0,32%
Gold spot
2.315,17
-0,30%
NY-Nasdaq Composite
15.696,64
+1,59%
Stijgers
Dalers